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The Regulation of RhoA by StarD13 in Focal Adhesions is 
Essential for Astrocytoma Cell Motility 
 
 
Bechara A. Saykali 
 
 
ABSTRACT 
 
 
 
The World Health Organization estimates that glioblastoma account only for 2% of 
all cancers. Diagnosis of these types of tumor is often misleading, resulting in a false 
treatment and fatalities. Astrocytes rarely exhibit metastasis; but high incidence of 
spreading within the brain is recorded. Cells display different types of actin protrusions, 
namely, lamellipodias, filopodias, invadopodias, in order to complete the motility cycle. 
The small Rho GTPases, RhoA, Rac1 and Cdc42 are now widely accepted as having a 
major role in motility, by cycling between an active and inactive state. StarD13 have 
been shown to play the role of a GTPase activating protein, for both RhoA and Cdc42. 
RhoA was tested for its controversial role in the progression of tumors in 
astrocytoma. First, the ability of StarD13 to control motility was tested. Data show that 
StarD13, in fact, do regulate motility. The cycle of RhoA and Rac1 GTPases were then 
investigated as to activation and effect on migration. Data confirm that StarD13 in fact 
regulate the activation of RhoA, which in turn regulates Rac1 activity. A RhoA Fret 
biosensor was used to further study RhoA’s activation pattern and localization, which 
demonstrates that RhoA cycles between active and inactive at the edge of the cell. 
These Data suggest that StarD13 has an important role in regulating motility in 
astrocytomas. This effect is achieved by controlling RhoA activity, which in turn 
impacts Rac1 activity. 
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Chapter I 
LITERATURE REVIEW 
1.1. Cancer background 
1.1.1. Overview 
The National Cancer Institute (2012) estimates that 12 million individuals 
were characterized with cancer only in America. About 1,638,910 new cases 
were later diagnosed between 2011 and 2012, and around 577,190 Americans 
mortality counts were recorded in 2012, in a rate of 1500 death per day. 
The American Cancer Society (2012) defines cancer as a group of genetic 
diseases characterized by abnormal cell growth and their ability to spread into 
different parts of the human body. The absence of the invasion feature will result 
in a benign neoplasm. The presence of both features will characterize the tumor 
as a malignant neoplasm, or in other term, having cancer. The malignant 
phenotype almost always require mutation in one or more of the genes involved 
in cell proliferation, survival, DNA repair, motility, invasion and angiogenesis 
(Ferrera & Kerbel, 2005). Key genetic alterations are needed for tumor initiation 
and advancement. A tumor arises when the constituting cells are immortalized, 
and obtains the capability of infinite self-renewal. This is attained when the cells 
produce human telomerase reverse transcriptase (Kim et al., 1994). The cells 
then become “self sustaining”, where most signaling pathway become 
constitutively active, with no need for extracellular factors (Persson, 2008). An 
important feature for tumor progression is evading apoptosis. This is achieved by 
overexpression of anti-apoptotic proteins such as BCL-2, or in mutation in cell 
cycle proteins such as p53 (Reed et al., 1996). An addition key process for 
tumorigenic cells is escaping immune detection. Cancerous cells will down 
regulate the antigen presenting, major histocompatibility complex and secrete 
immunosuppressors (Drake et al., 2006). The final feature is the acquisition of 
invasive capacity. This involves the activation if several proteins, which act in, 
cell adhesion and migration (Persson, 2008). 
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1.1.2. Cancer staging and classification 
Improvements in cancer staging and classification are central for 
advancements in cancer treatment (Chen, 2012). In accordance with the US 
National Cancer institute (2010), a cancer stage describes the severity of a 
person’s cancer. This is based on the extent of the primary tumor and whether or 
not this tumor has metastasized. Most tumors range from stage o to stage IV. 
Still, the anatomical extent of the disease remains the main and most powerful 
tool to diagnose cancer. This is achieved according to the TNM classification 
(Goldstraw, 2013). It is based on the extent of the tumor (T), the extent of spread 
to lymph nodes (N), and the presence of distant metastasis (M). A number is 
added to each letter to indicate the size or extent of each characteristic (Vecchi, 
Brechot & Lebeau, 1998; Goldstraw, 2013). 
Tumors can be classified in two ways: according to the tissue in which it 
originated or the location in the body where it developed (National Cancer 
Institute, 2012). In agreement with the first classifications, six major categories 
can be found: carcinoma for epithelial tissues, sarcoma for non-epithelial tissues, 
leukemia and lymphoma for hematopoietic and lymphoid tissues, myeloma for 
plasma cells in the bone marrow and the mixed category (Fenton & Longo, 2007; 
National Cancer Institute, 2012). Recent publications describe novel approaches 
to classify cancer types using various genome-wide molecular techniques (Golub 
et al., 1998; Ringnér, Staaf, & Jönsson, 2013).  
1.1.3. Brain cancer 
The first attempt to classify brain tumors, was published in 1829, by 
Cruveilier, where these tumors where classified as being bony, fleshy or fatty 
clusters (Cruveilhier, 1829). The most recent classification used today, is the 
World Health Organization (WHO) Classification, established in the 1980s. The 
classification of the WHO was put according to histologic classification criteria. 
The tumors are mainly classified as being glial or non-glial. Glial tumors are 
malignancies in the glial cells, which are the neural supportive cells. The most 
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common neuroepithelial (glioma) tumor in the WHO-system are astrocytic, 
oligodendroglial and the mixed oligo-astrocytic tumors. Gliomas can vary from 
intermediate-grade to high-grade, in other terms, from fairly aggressive to highly 
aggressive (Manoj, Kalyani, Jyothi, Ganga, & Govardhani, 2011). Grade I 
glioma occur only in juveniles, and are usually considered benign, whereas, 
Grade II-IV are predominantly found within the cerebral hemispheres of adults. 
The non-glial tumors are also further sub classified into: Acoustic schwannoma, 
Craniopharyngioma, Meningiomas, Medulloblastoma, Primary CNS lymphoma, 
and tumors related to the pineal and pituitary glands (Collin, 2004). The 
remainder of this thesis paper will shed light specifically and exclusively on 
gliomas since they are the most common, constituting approximately 50% of 
brain cancer cases. 
1.1.4. Predisposition and diagnosis 
The genetic factors associated with brain tumor formation are still not 
known. It is thought that individuals, who develop brain cancer, inherit a 
germline mutation in a tumor suppressor gene. Tumors initiate when the 
remaining normal copy of the tumor suppressor is mutated or silenced (Reilly, 
2009). To better understand the genetic background of brain cancer, it is 
normally associated with several familial cancers. These include Li-Fraumeni 
syndrome, neurofibromatosis, tuberous sclerosis and Turcot's syndrome. Li-
Fraumeni is caused by the mutation of a gene involved in the cell checkpoint 
TP53 and CHEK2, and Turcot’s syndrome is caused by mutations in genes 
involved in DNA repair (Hamilton et al., 1995; Bell et al., 1999). These cited 
syndromes, increase the risk of brain cancer occurrence by increasing DNA 
mutations, resulting in an uncontainable growth. Neurofibromatosis and tuberous 
sclerosis syndromes result after mutation in NF1, NF2, and TSC1, TSC2 
respectively. These genes play roles in inhibiting growth stimulating cellular 
signaling. It is thought that these illnesses increases brain cancer disposition by 
increasing cell growth (Friedman, Gutmann, MacCollin, Riccardi, 1999; Huson, 
Hughes, 1994). Even with the presence of such evidence, the search to 
understand the genetic basis of brain cancer is still challenging. The presence of 
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too many genetic variables and the lack of patient subjects make statistical 
studies insignificant. Even if enough patients were provided, the heterogeneity 
nature of the disease adds more variable to the equation (Reilly, 2009). 
A timely diagnosis of a given brain tumor is of utmost importance regarding 
surgery and patient survival. Commercial brain cancer treatments (drugs) are 
frequently toxic. The usage of these drugs is justified by the fact that it may lead 
to the patient’s survival. But the probability of the patient’s survival is directly 
linked to the appropriate treatment associated to the right patient, which is all 
linked to accurate diagnosis (Omuro, Leite, Mokhtari, Delattre, 2006). 
Contrariwise, the establishment of a brain cancer diagnosis is not always direct. 
On one hand, many non-neoplastic neurological illnesses can mimic some of the 
symptoms presented in brain neoplasm, to name a few: multiple sclerosis, stroke, 
pyogenic abscess, toxoplasmosis, and tuberculosis among many others. In such 
cases, diagnosis is sometimes missed, and patients are exposed to unnecessary 
surgical procedure (Okamoto et al., 2004; Okamoto et al., 2004).  On the other 
hand, several brain neoplasms may occur without manifesting the appropriate 
symptoms. This often leads to a delay in histological confirmation, i.e. diagnosis 
(Schrader, Barth, & Lang, 2000; Haldorsen, Espeland, Larsen, & Mella, 2005). 
According to DeAngelis, MD, the best test for diagnosis is Magnetic Resonance 
Imaging (MRI) with gadolinium enhancement (DeAngelis, 2001). Other 
references cite the invasive biopsy test as being the preferred method to diagnose 
cancer. This method provides about histological type, classification, grade, and 
potential aggressiveness. This information helps in determining the best 
treatment. The same references also argues that imaging techniques can’t be 
considered as being the ideal tests, since no quantification can be done on the 
tumor size (Nimsky, Ganslandt, Kober, Buchfelder, & Fahlbusch, 2001). Recent 
studies show promise of a new technology, which has the ability to provide fast 
and accurate detection, through the use of biosensors. This technique also 
provides reliable imaging of cancer cells, examination of angiogenesis and 
cancer metastasis, and the capability to determine the effectiveness of anticancer 
chemotherapy agents (Bohunicky & Mousa, 2010). 
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1.1.5. Treatment and signaling pathways 
The past century has seen the improvement of the four foundations of 
anti-cancer therapy: surgery, chemotherapy, radiation therapy and hematopoietic 
stem cell transplantation. Modern chemotherapy has adopted three main 
principles: multi-agent combination, dose intensity and early use. While being 
very effective, chemotherapy is not specifically active, which means that it 
targets macromolecules as DNA, and major metabolic pathways that are essential 
to both malignant and normal cells (Balis et al., 2002). Most traditional 
chemotherapy agents, namely, methotrexate, cytarabine, etoposide, fluorouracil, 
exert their cytotoxic effects by interfering with the synthesis or function of DNA 
and RNA (Stewart et al., 2004). 
This case is similar when approaching brain cancer therapy, where three 
factors limit the effectiveness of conventional treatments: The toxicity of the 
effective dose, the blood brain barrier (BBB), which restricts the penetration of 
anti-cancer agents, and the lack of specificity (Gutman, Peacock, & Lu, 2000). 
The standard treatment for brain tumors is of three stages: surgical resection, 
radiotherapy followed by chemotherapy. Despite the recent development of this 
technique, the patient prognosis for these patients is still relatively poor 
(DeAngelis, 2001). Today, the identification of specific characteristics and 
pathways of cancer has increased the level of understanding of the molecular 
aspect. This newly acquired knowledge generated specific therapies, which target 
pre-defined proteins in the neoplastic process, or via targeting drugs to the tumor 
(Wu, Chang & Huang, 2006). In the case of gliomas, the tumors exhibit high 
level of heterogeneity and show a large variability when it comes to gene and 
protein expression. Examples of these of these proteins are: The receptor 
Tyrosine kinase (RTK) and its downstream effector phosphatidylinositol 3-
kinase (PI3K), along with the deregulation of the p53 and Rb tumor suppressor 
pathways (Furnari et al., 2007; Chin et al., 2008).  Two main pathways have been 
shown to be active downstream of RTKs, and which carry key mutation in 
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gliomas: The PI3K signaling cascade and the MAPK signaling pathway, 
composed of Ras/Raf/MEK/ ERK-cascade (Persson, 2008).  
Mutation in the PI3K pathway will radically affect cell cycle behavior 
leading to neoplastic growth. This mutation is traced back to the interacting 
region between Pi3K’s two subunits: PIK3CA (catalytic) and PIK3R1 
(regulatory). This mutation disrupts the interaction between the subunits and 
result in a constitutively active PI3K (Huang et al, 2007; Chin et al, 2008). 
Another glioma-associated protein is PTEN, which is a tumor suppressor. PTEN 
acts antagonistically to PI3K by dephosphorylation of signal substrate. This 
tumor suppressor is found inactive in 25-40% in high-level gliomas by 
hypermethylation, causing loss of regulation of PI3K (Ohgaki et al., 2004; Chin 
et al., 2008). 
The second pathway is the MAPK pathway. A constitutively active, 
mutated Ras is a hallmark of most cancers: It is found mutated 50% of all human 
tumors. In the case of gliomas, fewer incidents of mutated forms of Ras are 
found, signifying that the increase of Ras activity is caused by an increase in 
upstream RTK activation and not through direct mutation (Furnari et al., 2007).  
1.2. Cellular motility cycle 
1.2.1. Overview 
For cells to move, scavenge for nutrients, undergo wound healing etc., 
many events should occur, of which is actin cytoskeleton remodeling, and 
formation of actin based phenotypes. These phenotypes are necessary for proper 
adhesion to the subcellular matrix, sensing the surrounding matrix for growth 
hormones and nutrients (Chen et al., 1985). They can be classified into two 
groups, where the first group results in two-dimensional locomotion (x, y), and 
the other resulting in motility in the third dimension (z). The former includes 
lamellipodia, filopodia and focal adhesion. Many characteristics differentiate 
them from each other, namely, location of formation, protrusive dimension, 
duration and the proteins involved (Murphy & Courtneidge, 2011). In the case of 
3D locomotion, two main structures are to be noted, podosomes and 
invadopodia. 
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1.2.2. Actin model 
As mentioned above, cells would move in 2D or 3D according to its need 
and environment (Murphy & Courtneidge, 2011). Different cells use different 
ways for locomotion, but the rearrangement of the cytoskeleton is common to all 
those mechanisms. For the cell to migrate in two dimensions, a shift is required 
from a non-polarized into a polarized state. This transition will acquire the cell a 
motile phenotype, where the cell’s front extends and attaches just behind the 
leading edge, forming focal contacts with the ECM. The cell’s rear would detach 
and retract.  When the cell’s rear detaches, and focal contacts mature into focal 
complexes, the cell can now pull itself forward. For these events to occur, major 
rearrangement of the cytoskeleton should happen, including actin, myosin, 
tubulin, and their binding proteins. Two structures are typically described in 2D 
migration, namely, lamellipodia and filopodia (Small, 1994). These structures are 
formed by the polymerization of monomeric globular actin or G-actin, which 
binds ATP, into filamentous actin (F-actin), a double helical actin structure. 
More specifically, actin monomers will nucleate via the actin binding proteins 
Arp 2/3, Ena/VASP proteins or DRFs, forming a faster growing filament, which 
has a positive growing end (blunt side) and a negative end (pointed). 
Incorporated G-actin will hydrolyze its bound ATP to become ADP bound F-
actin. Actin is recycled from the pointed end through ADF/cofilin. Severed actin 
monomers are re-phosphorylated via profilin, and then either stored with 
thymosin β, shuttled to the blunt end, or as profilin-actin complexes (Lambrechts 
et al., 2004). Furthermore, for the cell to move, a contractile force is needed, in 
addition to the polymerization procedure. This contractile force is established by 
the formation of actin-myosin complexes. Once established, these complexes use 
energy from ATP hydrolysis to drive the contraction (O’Connell et al., 2007). 
For optimal migration to occur, synchronization between polymerization and 
contractility must be present, both temporally and spatially. According to Olson, 
one explanation could be that both procedures are activated by the same GTPase 
but with different kinases. For example, the activation of RhoA (GTPase), results 
in actin polymerization, via RhoA’s binding to DRF1, whereas, acto-myosin 
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contractility is activated through ROCK or LMK (Olson & Sahai, 2009). This 
can lead to the activation of polymerization prior to contraction. Another 
explanation by the same author also states that activators of polymerization could 
also be inhibitors of contraction. For example, Activation of Rac1 activates 
WAVE dependent actin nucleation, while it also inhibits RhoA through 
production of ROS, which reduces contractility in this phase. Another theory, 
proposed by Hall (2009), states that polymerization occurs at the anterior end 
(front) while contraction occurs at the rear (posterior) and sides. 
Many other factors contribute to achieve proper cellular motility, making 
it a complex event. Any alteration in any of these factors will result in cellular 
transformation and carcinogenesis. Overexpression of certain proteins in motility 
pathways, as RhoGTPases, will aid the cells in acquiring an advanced motile 
phenotype, increasing its ability to migrate and invade. This process is vital for 
metastasis (Jiang, et al., 2009). 
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 Figure 1. Cell migration on 2-D substrates. Cell migration consists of the 
following four successive processes. Protrusion: when cells are polarized by 
extracellular stimuli; polymerized actin filaments induce the formation of 
membrane protrusions such as filopodia and lamellipodia. Adhesion: protruded 
membranes contact the substrate and; newly formed adhesion complexes are 
stabilized and mature into focal adhesions. Translocation: acto-myosin contractile 
forces translocate the nucleus and cell body. Retraction: cell-substrate adhesive 
structures at the trailing edge are disassembled, and the trailing edge retracts. 
Source: (Yamazaki, Kurisu & Takenawa, 2005). 
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1.3. Rho GTPases 
1.3.1. Overview 
Rho GTPases are monomeric G proteins, which range in size between 21 
and 30 KDa. Rho was identified as a member of the Ras superfamily in 1980s, 
due to its high homology to Ras, and was named after it (Ras homologue) (Yang, 
2002; Parada, Tabin, Shih, & Weinberg, 1982). The Ras superfamily is 
categorized into at least five families, namely, Ras, Rho, Rab, Ran and Arf 
(Bischoff, Molendijk, Rajendrakumar, & Palme et al., 1999). Many structural 
features bind this family, including four guanine nucleotide-binding domains, 
and an effector-binding domain. Up till now, twenty-two mammalian Rho 
proteins have been identified, belonging to the small Rho GTPases family. The 
family comprises of three isoforms of Rho (A, B and C), two isoforms of Rac (1 
and 2), one isoform of Cdc4, RhoG and TC10. Amongst the eight, RhoA, Rac1 
and Cdc42 are the most studied for their key role in regulation of cell motility 
(Tang, Olufemi, Wang, & Nie, 2008).  
An important feature of all GTPases is their ability to cycle between a 
GTP active and a GDP inactive state. While bound to GTP, these GTPases 
interact with downstream effectors to mediate a specific cell response event. Rho 
can intrinsically exchange and hydrolyze GTP in vitro. In vivo these processes 
are catalyzed a family of enzymes, including respectively, guanine-nucleotide 
exchange factors (GEFs) and GTPase activating factors (GAPs). Moreover, 
guanine-nucleotide dissociation inhibitor (GDI) also regulates Rho GTPases, 
through inhibition of any interaction between the GTPase and the membrane, but 
not necessarily with downstream targets (Yamazaki, Kurisu & Takenawa, 2005). 
A post-transcriptional modification, in all Rho proteins, consists of a prenylation 
on a conserved cysteine at the C-terminal, which helps them bind to the cell 
membrane. Point mutations in the C-terminal have been exploited in order to 
study these proteins in vitro. One mutation renders Rho proteins constitutively 
active, as the mutation inhibits GTPase activity. Another mutant, called dominant 
negative mutant, which have reduced affinity for nucleotide, therefore show 
reduced activity (Ridley, 2001). 
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Figure 2. The Rho GTPase cycle. They cycle between an active (GTP-bound) and an 
inactive (GDP-bound) conformation. In the active state, they interact with one of over 60 
target proteins (effectors). The cycle is highly regulated by three classes of protein: in 
mammalian cells, around 60 guanine nucleotide exchange factors (GEFs) catalyze 
nucleotide exchange and mediate activation; more than 70 GTPase-activating proteins 
(GAPs) stimulate GTP hydrolysis, leading to inactivation; and four guanine nucleotide 
exchange inhibitors (GDIs) extract the inactive GTPase from membranes. Source: 
(Burridge, & Chrzanowska-Wodnicka, 1996) 
1.3.2. Rho GTPases signaling and motility 
Rho proteins’ main role is to relay the signal from the plasma membrane 
receptor to the actin binding proteins. In order to regulate those proteins, their 
corresponding GEFs and GAPs are under tight control. In absence of any stimuli, 
Rho GEFs are found inactive in the cytosol near the membrane, which is 
maintained by interaction of the Pleckstrin domain (PH) and the Dbl homology 
domain (DH). In response to activating signals, this inhibition is relieved 
exposing the catalytic site allowing access to GTPases substrates. Not 
surprisingly, there are an increasing number of distinct classes of signaling 
molecules that have been shown to interact directly with RhoGEFs and stimulate 
their catalytic activity. These include phosphoinositides, protein tyrosine or 
serine/threonine kinases, heterotrimeric G protein Gα subunits and other 
regulators of small GTPases (Worthylake, Rossman, & Sondek, 2000). 
Increasing data show the involvement of the PI3K pathway after stimulation with 
platelet-derived growth factor PDGF or insulin (Kotani, 1994), and another 
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upstream signaling pathway for Rho is the pathway initiated by LPA through 
receptor tyrosine kinase (Small, 1994).  
Moving on to downstream effectors of Rho GTPases, literature shows that Rho 
affects cell motility by regulating the myosin light chain (MLC). Active Rho 
interacts with, and relieves the inhibition of ROCK through binding its PH 
domain. ROCK then promotes MLC phosphorylation by inhibiting MLC 
phosphatase. ROCK can also directly phosphorylate MLC, thereby enhancing 
myosin activation (Amano, 1997). Remarkably, it has recently been reported that 
ROCK is involved in induction of prolonged RhoA activation by 
phosphorylating and inactivating p190A RhoGAP (Mori, 2009). An alternative 
effector of Rho is LIMK. LIMK phosphorylates the actin-severing protein 
cofilin, inhibiting its function and leading to a net increase in filamentous actin 
(Bernard, 2007). Additional downstream effectors from Rho involved in actin 
regulation include members of the ezrin–radixin–moesin (ERM) family of 
proteins. ERM proteins function as adaptor proteins that link the cortical actin 
network to trans membrane receptors (Takai, Sasaki, & Matozaki, 2001).  
Rac1 and Cdc42 share as downstream effectors, the WASP/SCAR/WAVE 
family of scaffold proteins. They are considered mainly as nucleating factors, 
promoting the activation of the Arp2/3 complex resulting in actin rearrangement. 
Another key effector downstream to Cdc42 and Rac1 is the serine/threonine 
kinase, p21-activating protein (p65PAK). PAK is able to phosphorylate both 
MLCK and LIMK, inhibiting the former but activating the latter. This could 
theoretically reduce severing, which stabilizes actin polymerization at the leading 
edge. 
RhoA, Rac1 and Cdc42 strongly affect the motility cycle. These Rho GTPases 
regulate generation of polarity, actin protrusion, changes in adhesion, and 
generation of force, which are the four phases for motility acquisition. Of the 
three Rho GTPases mentioned above, Cdc42 is the most cited to effect cell 
polarity (Chant, 1999). In this phase Cdc42 will play a dual role, where it would 
activate microtubule organizing center (MTOC) for cell orientation and would 
activates Rac which then promotes localized actin polymerization and membrane 
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protrusions (Etienne-Manneville, & Hall, 2001). Once cell polarity is established, 
the next step would be the formation of the actin protrusion (Rottner, Hall, & 
Small, 1999). The main pathways involved in this second phase are essentially 
downstream effectors of Rac1, and are three: the regulation of Arp2/3 activity by 
WASP family verprolin-homologous protein (WAVE), the regulation of cofilin 
and myosin light chain kinase (MLCK) by Pak, and the regulation of actin 
capping proteins by PIP2 (Miki, Yamaguchi, & Suetsugu, 2000). Next, to 
promote motility, a cycle of up regulating focal adhesion and down regulating 
adhesions must occur (Beningo, Dembo, & Kaverina, 2001). Rho is of prime 
importance for establishment of these phenotypes, yet it’s not the only factor. 
Rac also can induce structure similar to those regulated by Rho. While no 
convincing evidence has been presented to distinguish the two structures, the 
differences, if any, are used to explain the mechanism of motility (Burridge, & 
Chrzanowska-Wodnicka, 1996). As much as the formation of focal adhesion is 
important for cell motility at the leading edge, the dissolution of focal adhesion at 
the tail of the cell is of equal significance. Rho signaling has been also found to 
play a role in focal adhesion dissolution, through its downstream effector Rho-
kinase (ROCK) (Alblas, Ulfman, & Hordijk, 2001). The fourth and final step is 
the generation of contractile forth. Stress fibers are the main actors in contraction 
generation, and are regulated by Rho (Ridley, & Hall, 1992). To generate this 
force, stress fibers should be anchored at both ends to cellular components, of 
which focal adhesion are most common (Nusrat, Giry, & Turner, 1995) 
Literature counts three different downstream effectors of Rho for stress fibers 
formation: ROCK, mDia and PI5K (Chrzanowska-Wodnicka, & Burridge, 1996; 
Satoh, & Tominaga, 2001; Chong, Traynor-Kaplan, & Bokoch, 1994). These 
pathways, involved in all these phases, are to a certain extent, conserved in 
evolution, and influence proteins that control both the actin and tubulin 
cytoskeleton. 
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Figure 3. Downstream effectors of Rac1 and Cdc42. Almost all GTPases eventually 
lead into an actin binding proteins, which regulates actin turnover. In this case, Rac and 
Cdc42 lead to activation of the Arp2/3 complex, which regulates actin nucleation and 
polymerization. Source: (Goldstraw, 2013). 
1.4. StarD13 or DLC2 
StarD13, also known as START-GAP2 or DLC2, was first described as a 
tumor suppressor in hepatocellular carcinoma (HCC) cells where it was found to 
be under expressed in human tissues (Ching et al., 2003). Beside its tumor 
suppressor characteristic, it was also found to have Rho-GAP function, where it 
was demonstrated to inhibit the Rho-mediated assembly of actin stress fibers 
(Ching et al., 2003). StarD13 shares 64% homology with DLC1, another member 
of the DLC family (Ullmannova & Popescu, 2006). StarD13 consists of an N-
terminal SAM motif and a C-terminal START domain. In addition, it contains a 
RhoGAP domain, which is important to its function (Ching, et al., 2003; 
Thorsell, et al., 2011; Ullmannova & Popescu, 2006). It was shown, that under 
expression of DLC2 helps for invasion and migration of hepatocellular 
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carcinoma cells (Leung et al., 2005). Another report by Leung has shown that 
StarD13 inhibits cell growth by down regulating the Raf-1-ERK1/2-p70S6K 
signaling pathway (Leung, Yam, Chan, Ching, & Ng, 2010). Another report 
states a potential role for StarD13 in angiogenesis, where a StarD13 KO mouse 
model was established (Lin et al., 2010). This study highlights the importance of 
StarD13 in cancer cell motility, specifically in astrocytomas, by playing the role 
of RhoA GAP. Furthermore this study investigates the importance of RhoA and 
Rac1 cycling as to the cell motility cycle. 
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Chapter II 
MATERIALS AND METHODS 
 2.1. Cell culture 
Human astrocytoma cell lines SF268 and T98G were cultured in DMEM 
medium supplemented with 10% FBS and 100U penicillin/streptomycin at 37°C 
and 5% CO2 in a humidified chamber. 
2.2. Antibodies and reagents 
Goat polyclonal anti-StarD13 and anti-Cdc42 antibody (Sc-87) antibody were 
obtained from Santa Cruz Biotechnology, USA. Mouse monoclonal anti-RhoA, 
mouse monoclonal anti-Rac1, and mouse monoclonal anti-paxillin antibodies were 
purchased from Upstate biotechnology, Lake Placid, NY. Anti-goat and anti-mouse 
HRP-conjugated secondary antibodies were obtained from Promega. Fluorescent 
secondary antibodies (AlexaFluor 488) and Rhodamin Phalloidin were obtained 
from Invitrogen. The full length GFP-StarD13 construct was a generous gift from 
Dr. Hitoshi Yagisawa from the University of Hyogo, Japan (Mammalian expression 
plasmids for GFP fusion proteins, pEGFPSTART-GAP1 (wt)). The RhoA 
constructs were a generous gift from Dr. Hideki Yamaguchi from the Albert 
Einstein College of Medicine, New York, USA. 
2.3. Cell transfection and small interfering RNA 
Cells were transfected with 5 mg GFP-StarD13, Dominant active RhoA, 
dominant active Rac, or control empty GFP alone vectors using Lipfectamine LTX 
with Plus reagent (Invitrogen) as described by the manufacturer. Cells were 
incubated with the transfection complexes for 4 hours then refed with DMEM 
supplied with 30% FBS. The experiments were carried on 24 hours following 
transfection.  Goat FlexiTube siRNA for StarD13, RhoA, and Rac1 were obtained 
from Qiagen. The siRNAs used had the following target sequences:  
StarD13: Oligo 1, 5’-CCCGCAATACGCTCAGTTATA-3’ and  
Oligo 2, 5'-ATGGCTACATCCCTACTAATA-3',  
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RhoA: 5’-TTCGGAATGATGAGCACACAA-3’, and  
Rac1: 5’-ATGCATTTCCTGGAGAATATA-3’. The cells were transfected with the 
siRNA at a final concentration of 10 nM using HiPerfect (Qiagen) as described by 
the manufacturer. Control cells were transfected with siRNA sequences targeting 
GL2 Luciferase (Qiagen). After 72 hours, protein levels in total cell lysates were 
analyzed by western blotting using the appropriate antibodies or the effect of the 
corresponding knockdown was assayed. 
2.4. Pull down assays and Western Blots 
Cells were starved in low-glucose Opti-MEM medium without FBS for 3 hours, 
and stimulated with a final concentration of 10 nM Recombinant Human Epidermal 
Growth factor (Hu EGF) for various times (Invitrogen). Cells were then lysed and 
the pull-down assay performed using the RhoA/Rac1/Cdc42 Activation Assay 
Combo Kit (Cell BioLabs) following the manufacturer’s instructions. Briefly, cell 
lysates were incubated with GST-RBD (for Rho pull down) or GST-CRIB (for the 
Rac and Cdc42 pull down) for 1 hour at 4 °C with gentle agitation. Then, the 
samples were centrifuged, and the pellet washed for several times. After the last 
wash, the pellets were resuspended with sample buffer and boiled for 5 minutes. 
GTP-RhoA or GST-Rac/Cdc42 was detected by western blotting using anti-RhoA, 
anti-Rac or anti-Cdc42, respectively. Total RhoA/Rac and Cdc42 were collected 
prior to the incubation with GST-RBD/GST-CRIB and used as a loading control. 
The levels of protein expression were compared by densitometry using the ImageJ 
software. 
2.5. Immunostaining 
The cells were plated on cover slips, and the appropriate treatment was applied. 
Cells were fixed with 4% paraformaldehyde for 10 minutes, and permeabilized with 
0.5% Triton-X100 for 10 minutes. To decrease background fluorescence, cells were 
rinsed with 0.1 M glycine then incubated with 0.1 M glycine for 10 minutes. For 
blocking, cells were incubated 4 times with 1% BSA, 1% FBS in PBS for 5 
minutes. Samples were stained with primary antibodies for 2 hours and with 
fluorophore-conjugated secondary antibodies for 2 hours. All fluorescent images 
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were taken using 60X 1.4 NA infinity corrected optics on a Nikon Eclipse 
microscope supplemented with a computer-driven Roper cooled CCD camera and 
operated by IPLab Spectrum software (VayTek). 
2.6. Wound healing and motility assays 
Cells were grown to confluence on culture plates and a wound was made in the 
monolayer with a sterile pipette tip. After wounding, the cells were washed to 
remove debris and new medium was added. Phase-contrast images of the wounded 
area were taken at 0 and 24 hours after wounding using a 10X objective. Wound 
widths were measured at 11 different points for each wound, and the average rate of 
wound closure was calculated in mm/hr. For motility analysis, images of cells 
moving randomly in serum were collected every 60 seconds for 2 hours using a 20X 
objective. During imaging, the temperature was controlled using a Nikon heating 
stage which was set at 37 °C. The medium was buffered using HEPES and overlaid 
with mineral oil. The speed of cell movement was quantified using the ROI tracker 
plug-in in the ImageJ software, written by Dr. David Entenberg. This was used to 
calculate the total distance travelled by individual cells. The speed is then calculated 
by dividing this distance by the time (120 minutes) and reported in mm/min. The 
speed of at least 15 cells for each condition was calculated. The net distance 
travelled by the cell was calculated by measuring the distance travelled between the 
first and the last frames. Both assays were done using infinity corrected optics on a 
Nikon Eclipse microscope supplemented with a computer-driven Roper cooled 
CCD camera and operated by IPLab Spectrum software (VayTek).  
2.7. RhoA FRET biosensor imaging and analysis  
SF268 cells were transfected with 1 mg of the RhoA fluorescence resonance 
energy transfer (FRET)-based biosensor plasmid described earlier. FRET image 
sequences were obtained with an automated Olympus IX70 microscope equipped 
with filter wheels in the excitation and emission light path and coupled to a cooled 
SensiCam QE CCD camera (Cooke Corp., MI). CFP was excited using a S430/25 
filter with a Sutter DG4 illuminator (Sutter Instruments, Novato, CA) and the 
fluorescence detected with a S470/30 (donor image) or S535/30 (FRET image) 
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emission filter. YFP was imaged with exciter S500/20 and emitter S535/30 (YFP 
image). In all cases a dual-band dichroic mirror 86002v2bs was used (Chroma 
Technology Corp., VT). Images were background corrected and the YFP images 
were thresholded to generate a binary mask with values of 1 within the cell and 0 
for the background. The increase in FRET signal due to activation of RhoA was 
detected by ratioing the FRET image (CFP excitation- YFP emission) to the donor 
image (CFP excitation- CFP emission). FRET signals were quantified by averaging 
the mean FRET ratio in cells. For the live FRET movies, the cells were transfected 
with the RhoA biosensor as described above, and images of the cells moving 
randomly in serum were taken at a 1 minute time interval for 1 hour. The images 
from each frame were analyzed as described above. Detailed description of the 
image analysis process is described earlier.  
2.8. Adhesion assay  
96-well plates were coated with collagen using Collagen Solution, Type I from 
rat tail (Sigma) overnight at 37 °C then washed with washing buffer (0.1% BSA in 
DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37 °C in a 
CO2 incubator for 1 hour. Next, the plates were washed and chilled in ice. 
Meanwhile, the cells were trypsinized and counted to 4x105 cell/ml. 50 µl of cells 
were added in each well and incubated at 37°C in a CO2 incubator for 30 minutes. 
The plates were then shaken and washed 3 times. Cells were then fixed with 4% 
paraformaldehyde at room temperature for 10 minutes, washed, and stained with 
crystal violet (5 mg/ml in 2% ethanol) for 10 minutes. Following the staining with 
crystal violet, the plates were washed extensively with water, and left to dry 
completely. Crystal violet was solubilized by incubating the cells with 2% SDS for 
30 minutes. The absorption of the plates was read at 550 µm using a plate reader.  
2.9. Statistical analysis 
All the results reported represent average values from three independent 
experiments. All error estimates are given as mean ± SEM. The p-values were 
calculated by t-tests or chi-square tests depending on the experiment using the 
VassarStats: (http://vassarstats.net/).    
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Chapter III 
RESULTS 
 
3.1 StarD13 is important for astrocytoma cell motility 
To investigate the role of StarD13 in the motility of astrocytoma cells, we knocked 
down its expression using a siRNA oligonucleotide and confirmed the knockdown by 
western blot (Figure 1A). We then determined the effect of StarD13 knockdown on the 
rate of wound closure in a wound healing assay as well as individual cell speed and net 
distance migrated in time lapse assays. The knockdown of StarD13 significantly 
decreased the wound closure rate and this effect was confirmed using two different 
StarD13 siRNA oligonucleotides (Figure 1B and C). The decrease in cell migration 
due to StarD13 knockdown was successfully rescued by expressing a GFP-StarD13 
construct (Figure 1C). Furthermore, StarD13 knockdown significantly decreased the 
average speed of individual cells from 0.44 µm/min to 0.24 µm/min (Figure 1E) and 
the net distance migrated from 8.5 µm to 3.02 µm (Figure 1D and E and movie S1). 
Altogether these results show that the knockdown of StarD13 inhibits astrocytoma cell 
motility. 
 
 
Figure 4. StarD13 Knockdown. Two SiRNA oligos were transfected then protein 
extracts were used to assess protein expression against actin control. 
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Figure 5. StarD13 knockdown effect on motility by wound healing. (B) Cell motility 
was tested after StarD13 knockdown at 0 and 24 hrs. (C) Quantification of the wound 
healing assay show decrease in motility, which was rescued by StarD13-GFP construct. 
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Figure 6. Effect of StarD13 knockdown on motility by time lapse. (D) cell motility 
was tested in a 2 hour time lapse. (E) Quantification shows decrease in both cell speed 
and net path.  
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3.2 The effect of StarD13 knockdown on cell motility is through RhoA. 
 
StarD13 was described as a GAP for RhoA and Cdc42 but not for Rac. This was 
confirmed by the pull-down assays we performed to determine the activation levels of 
RhoA, Cdc42, and Rac in cells overexpressing StarD13, which show higher RhoA and 
Cdc42 activation in control cells as compared to cells overexpressing StarD13 (Figure 
2A). The overexpression of StarD13 also led to inhibition of stress fiber formation 
(Figure 2B), a process mediated by the cooperative activity of ROCK and mDia, which 
are downstream effectors of RhoA. This suggested that the effect of StarD13 on cell 
motility is mediated through its effect on RhoA or Cdc42. To mimic StarD13 knock 
down, we overexpressed RhoA in these cells. Indeed the expression of a dominant active 
form of RhoA inhibited cell motility similar to StarD13 knockdown. In the wound 
healing assay (Figure 2C), dominant active RhoA decreased cell motility from 7 µm/hr 
to 2.7 µm/hr (Figure 2D). Similarly, dominant active RhoA decreased the average cell 
speed from 0.34 µm/min to 0.25 µm/min (Figure 2F and S2). However, what was more 
substantial is the decrease in the net path in the cells transfected with dominant active 
RhoA from 9.31 µm to 1.43 µm (Figure 2E and F and movie S2).  
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 Figure 7. Effect of Rho A on motility. (A) GFP-StarD13 was transfected into T98 cells, and 
RhoA and Cdc42 activation was assayed for through pulldown. (B) Immuostaining for  GFP 
and actin, after GFP-StarD13 transfection, was performed. (C)(D) wound healing and time 
lapse were done to study the effect of DA-Rho transfection. (D)(F) quantification of the wound 
healing and time lapse show a decrease in cell motility. 
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3.3 The effect of StarD13 knockdown on cell motility is through Rac1. 
 
Surprisingly, the level of Rac activation showed a slight increase in cells 
overexpressing StarD13 (Figure 3A). In fact, the knockdown of RhoA does lead to 
increased levels of Rac activation (Figure 3B).  Accordingly, the knockdown of Rac by 
siRNA as verified by western blot (Figure 3C) inhibited cell motility similar to StarD13 
knockdown. In the wound healing assay (Figure 3D), Rac1 knockdown decreased the 
wound closure rate from 8.22 µm/hr to 1.76 µm/hr (Figure 3D and E). Likewise, there 
was a significant decrease in the cell speed from 0.44 µm/min to 0.17 µm/min (Figure 
3G and movie S3) and the net distance migrated from 8.50 µm in controls to 1.7 µm 
(Figure 3F and G and movie S3). 
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 Figure 8. Effect of Rac1 on motility. (A) GFP-StarD13 was transfected into T98 cells and Rac1 
expression was studied. (B) The antagonistic effect between RhoA and Rac1 was tested after RhoA 
knockdown. (C) Rac knockdown was performed in order to test its effect on motility. (D)(F) show 
the effect of Rac1 on motility via wound healing and time lapse. (E)(G) Quantification show a 
decrease in motility after Rac1 knockdown. 
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3.4 StarD13 knockdown inhibits the cycling in RhoA activation and 
prevents tail retraction. 
 
The fact that the constitutive increase in RhoA is inhibiting motility implies that 
RhoA has to be inactivated at some point in the cell motility cycle for the cells to move 
efficiently. To investigate this possibility, we stimulated cells with EGF and directly 
measured the level of activation of RhoA by pull-down assay at 0, 0.5, 1, and 3 minutes 
following stimulation. The results showed that RhoA activity increases significantly 
after 30 seconds of stimulation and then decreases after 1 minute. This activation 
persisted in StarD13 knock down cells (Figure 4A). An essential event for the 
completion of the cell motility cycle is the retraction of the tail (Figure 4B upper panel). 
The knockdown of StarD13 inhibited this retraction event (Figure 4B lower panel), and 
this was correlated with high persistent RhoA activation in the tail as seen in cells 
transfected with a RhoA FRET biosensor (Figure 4C lower panel, compared to upper 
panel). Indeed StarD13 knockdown cells showed an increased adhesive ability on a 
collagen matrix (Figure 4D and E).  
 
 
 
 
 
 
 
Figure 9. RhoA cycling. RhoA activity was studied after EGF stimulation, 
and was found to be most active at 30 seconds. RhoA activity then 
decreased at 1 minute. 
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Figure 11. Tail retraction decreased after StarD13 knockdown.  Time laps show Tail 
retraction decrease after StarD13 knockdown. 
Figure 10. RhoA localization. FRET shows activation of RhoA at the leading edge (upper 
panel). Lower panel show the persistent activation of RhoA after StarD13 knockdown (lower 
panel). 
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3.5 StarD13 affects the activity of RhoA at the cell edge. 
 
It has been reported that StarD13 localizes to focal adhesions in HeLa cells [22] and 
we detected RhoA activation at the edge of cells as well as the tail (Figure 5A). 
Accordingly we suspected that, other than its effect at the cell tail, StarD13 knockdown 
inhibits cell motility by altering the dynamics of cell adhesions at the cell edge. Indeed, 
other than its cycles of activation and inactivation at the tail of cells undergoing 
movement (4C and 5A-i and ii and movie S5), RhoA shows cycles of activation and 
inactivation at the leading edge of the cells towards the direction of movement as well 
(Figure 5A-iii and movie S6). RhoA activation was more persistent in cells where 
StarD13 was knocked down and it seemed to localize to adhesion structures, which were 
also more persistent (Figure 5B and movie S7).  
 
Figure 12. StarD13 effect on adhesion. StarD13 knockdown increases 
motility by up regulation RhoA. 
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Figure 13. StarD13 knockdown show persistent activation of RhoA. (A) StarD13 knockdown show 
activation of RhoA at the cell edges, after transfection of the RhoA biomolecular sensor. (B) StarD13 
also show increased activation of RhoA by FRET. 
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3.6 Roles of RhoA and Rac1 in cell adhesion dynamics. 
 
Rac has been shown to stimulate the assembly of focal complexes [26, 27]. In order 
to confirm that Rac plays this role in astrocytoma cells, we knocked down Rac1 and 
immunostained the cells using an antibody against paxillin, a component of focal 
complexes and focal adhesions [28]. Rac1 knockdown abolished any forms of adhesions 
(Figure 6A). We then wanted to verify that RhoA is essential for the maturation of focal 
complexes into focal adhesions similar to previous reports in other systems [29]. This 
was indeed verified, as the silencing of RhoA in astrocytoma cells led to the absence of 
mature focal adhesions. Only punctate small adhesions, which are most probably 
immature focal complexes, were evident (Figure 6A). These focal complexes were Rac-
dependent since in knocking down Rac in the RhoA knockdown cells abolished the 
formation of the focal complexes (Figure 6A). The increase in focal complexes in the 
RhoA knockdown cells is either due to the lack of maturation to focal adhesions or due 
to the increase in Rac activation, which is a by-product of RhoA knockdown as seen in 
Figure 3B. This phenotype was followed by a loss of motility in the Rho knockdown 
cells, showing that focal complexes alone are not enough for the cells to move and that 
RhoA activation in needed for cell motility. Following the verification of the role of 
RhoA in the maturation of focal complexes into focal adhesions, we aimed at addressing 
the question whether the inactivation of RhoA is essential for the disassembly of focal 
adhesions, which is in turn necessary for the completion of the motility cycle. This was 
indeed proven, as the transfection of cells with the dominant active RhoA led to an 
increase in the size of focal adhesions (Figure 6A). Also consistently, Figure 6A shows 
the exaggerated focal adhesions and lack of focal complexes in cells transfected with 
StarD13 siRNA (due to persistent RhoA activation). A phenotype, which reflects 
persistent, increased adhesion with lack of dissolution of focal adhesions and which was 
rescued through the transfection of GFP-StarD13 in the StarD13 KnDn cells (Figure 
6A). 
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Figure 14. Rac1 and RhoA affects adhesion through different actin structures. (Upper panel) 
from left to right, immunostaining show the different phenotypes each Rac1 and RhoA, where Rac1 
is responsible for focal complexs and RhoA is responsible for focal adhesions. 
Figure 15. Rac1 regulates motility downstream of RhoA and StarD13. Transfection of DA-Rac1 
rescues the decrease in motility after StarD13 knockdown. 
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Chapter IV 
DISCUSSION 
 
StarD13 is a Rho GAP that inhibits the activity of RhoA and Cdc42 (Ching et al., 
2003). StarD13 was also found to inhibit cell motility in hepatocellular carcinoma, 
which was consistent with its role as a tumor suppressor (Tang et al, 2012). However, its 
role in astrocytoma has never been studied. In the current study, we investigate the role 
of StarD13 in astrocytoma cell motility. This was highly intriguing given the crucial role 
of Rho GTPases, the downstream effectors of StarD13, and focal adhesions to which 
StarD13 localizes in cell motility and tumor invasion. To our surprise, and in contrast to its 
role as a tumor suppressor, the knockdown of StarD13 decreased the migration of 
astrocytoma cells. In order to confirm the specificity of this effect, we used a second 
StarD13 siRNA oligonucleotide that also resulted in a similar inhibition in cell motility. In 
addition, the expression of wild type StarD13 in cells with StarD13 knockdown was able to 
restore cell migration to a level similar to wild type cells. This further confirms that the loss 
of StarD13 in cells transfected with the StarD13 siRNA is indeed responsible for the 
decrease in cell motility observed. Previous reports that investigated the role of StarD13 
in cell motility showed that it negatively regulates motility (Tang et al, 2012). However, 
there are no previous reports on the role of StarD13 in astrocytoma or glioblastoma cells. 
The inconsistency between our results and the previous report could be due to the fact 
that the dependence of migration on RhoA-governed adhesion turnover is different in 
distinct cell types. Indeed, in glioblastoma, the model that we are investigating in the 
current study, the aberrant increase in RhoA activity has been linked to impaired cell 
migration through inducing profound morphological changes including the 
rearrangement of actin into stress fibers and the formation of focal adhesions. These 
changes, which are mainly linked to RhoA activity, increased the attachment of cells to 
matrix and rendered them immobile (Goldberg & Kloog, 2006). At least two reports 
show that DLC1 positively regulates cell migration similar to our data with DLC2 
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(Kawai et al., 2009; Lukasik, Wilczek, Wasiutynski, & Gornicka, 2011). We showed, 
directly through the decrease of RhoA activation in cells overexpressing StarD13 and 
indirectly through the complete absence of stress fibers in these same cells that StarD13 
indeed functions as a GAP for RhoA in astrocytoma cells. We also confirmed that 
StarD13 localizes to focal adhesions in these cells. Hence, we hypothesized that the 
knock down of StarD13 led to the constitutive activation of RhoA in focal adhesions, 
which in turn inhibited cell motility. In order to mimic the effect of StarD13 knock down 
and to determine the effect of the constitutive activation of RhoA on cell motility, we 
transfected astrocytoma cells with dominant active of RhoA. Indeed, this resulted in 
decreased cell motility similar to the knock down of StarD13. The decrease in cell 
motility due to the constitutive activation of RhoA has been reported before in other 
systems (Banyard et al., 2000; Li et al., 2010; Tkach et al., 2005; Vial et al., 2003). In 
fact, the correlation of RhoA expression and activity with brain tumor progression and 
cell motility remains a highly debatable issue in the literature. Our results show that the 
knockdown of RhoA using siRNA decreases the motility of cells. A previous study has 
reported that RhoA is needed for the migration of glioma cells in response to 
lysophosphatidic acid (LPA), an agent that is able to strongly induce chemokinesis and 
chemotaxis in human glioma cells (Manning et al., 2000). Moreover, the use of RNA 
interference to deplete mDia1, another downstream effector of Rho, inhibited both 
adhesion turnover and cell polarization in rat C6 glioma cells, which rendered them 
unable to undergo directed migration (Yamana et al., 2006). Indeed, a positive role of 
RhoA or its downstream effectors in cell motility and invasion has been described in 
many cell systems (Hakuma et al., 2005; Ridley, 2001; Sahai & Marshall, 2003; 
Takaishi et al., 1993; Worthylake et al., 2001). On the other hand however, inhibition of 
the RhoA effector ROCK has been shown to enhance the invasive and migratory 
properties of glioblastoma cells (Salhia et al., 2005). Interestingly, we detected a slight 
increase in Rac activation when StarD13 was overexpressed, which is consistent with 
the antagonistic relationship between RhoA and Rac activity we also observed in these 
cells. Hence, the inhibition of astrocytoma cell motility when StarD13 is knocked down 
could be secondary to Rac inhibition caused by the constitutive activation of RhoA. To 
investigate this possibility, we determined the individual effects of Rac knock down on 
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cell motility. The absence of Rac did indeed inhibit cell motility. Importantly, the 
transfection of StarD13 knock down cells with active Rac was able to completely restore 
cell motility to normal levels (Figure 6). Collectively, the previously discussed 
observations suggest that the constitutive activation of RhoA in the absence of StarD13 
could be inhibiting cell motility either directly or indirectly through inhibiting Rac or a 
combination of both.  
After verifying that StarD13 localizes to focal adhesions in astrocytoma cells (data 
not shown), and in order to determine the mechanism through which StarD13 
knockdown is inhibiting motility, we started investigating the hypothesis that the 
knockdown of StarD13 leads to constitutive activation of RhoA in focal adhesions, 
which leads to the stabilization of focal adhesions by preventing their disassembly and 
ultimately inhibiting cell migration. A high level of focal adhesions inhibits cell 
migration because of the strength of attachment to the extracellular matrix (Cox, Sastry,  
& Huttenlocher, 2001). At the tail, RhoA activation in adhesion complexes must be 
inhibited since tail detachment can often be the rate-limiting step of cell migration 
(Ridley, 2001) (Figure 7, left panel). Time-lapse movies of StarD13 knockdown cells 
showed that a large proportion of cells were unable to move forward due to their 
inability to retract their tail. This was accompanied by persistent activation of RhoA at 
the cell tail as revealed by FRET analysis. Hence, StarD13 might be playing a role in the 
inhibition of RhoA in focal adhesions at the tail of cells, which seems to be an important 
event for the cells to be able to detach their tails and to pull themselves and move 
forward. Our results verified this hypothesis, as StarD13 silencing induced the formation 
of larger and thicker focal adhesions especially at the tail of cells. This was also 
supported by the fact that cells with StarD13 knockdown were more than two times 
more adhesive to collagen than control cells. The increase in adhesion could have 
prevented the retraction of the tail, which we suspect is the major event that impeded 
cell motility. Similar to StarD13 knockdown, dominant active RhoA led to the formation 
of larger focal adhesions. This shows that StarD13 silencing mimics the effect of 
dominant active RhoA on adhesion in addition to cell motility.  
One instance where RhoA could be needed in cell motility is for the stabilization of 
protrusions through inducing the maturation of focal complexes into focal adhesions, a 
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process that we have shown to be inhibited in the absence of RhoA as previously 
discussed. Focal complexes are small punctate structures formed behind the front of the 
lamellipodium. These structures do not confer enough contractility needed for cell 
motility. Focal complexes are precursors for focal adhesions, which appear larger in size 
and less persistent (Kaverina, Krylyshkina, & Small, 2002), and are needed to provide 
the cell with the mechanical strength needed for the cell body to contract and move 
forward (Gupton, & Waterman-Storer, 2006). However, in order for RhoA to be able to 
drive the conversion of focal complexes into focal adhesions, Rac must first induce the 
formation of these focal complexes. This is confirmed by our results that show the 
absence of both focal complexes and focal adhesions when Rac is knocked down. On the 
other hand, cells showed exaggerated focal complexes with a complete absence of focal 
adhesions when RhoA was knocked down. Indeed, in fibroblasts, it was shown that 
initial cell spreading is associated with the formation of focal complexes and with high 
Rac activation (Kaverina, Krylyshkina, & Small, 2002). Formation of focal complexes 
stabilizes the lamellipodium of migrating cells by binding to the ECM (Condeelis et al, 
2001). Some studies described a high FAK activation during initial cell spreading, which 
potentiates Rac1 activation and suppresses RhoA activation (Chang, Lemmon, Park, & 
Romer, 2007; Ren et al., 2000). This also suggests sequential roles of Rac and RhoA in 
adhesion, whereby initially RhoA activation is suppressed allowing Rac-dependent focal 
complex formation and allowing the cells to spread. This is followed by high RhoA 
activation which leads to the maturation of focal complexes into focal adhesions. The 
activation of RhoA possibly leads to the local inhibition of Rac in order to allow the 
focal complexes to mature (Figure 7, right panel). As previously discussed, we did 
indeed observe an increase in Rac activation when RhoA was knocked down or when 
StarD13 was overexpressed. Indeed, it is classically accepted that RhoA and Rac cross 
talk and that they tend to have an inverse relationship (Sander et al., 1999). A 
mechanism through which Rac inhibits Rho was proposed, whereby Rac mediates the 
production of oxygen radicals, which causes the phosphorylation and activation of 
p190RhoGAP. This, in turn, results in the inactivation of Rho (Nimnual, Taylor, & Bar-
Sagi, 2003). Recently, it was shown that Rho leads to the inhibition of Rac through the 
ROCK-dependent Rac GAP, filamin GAP (FilGAP) (Ohta, Hartwig, & Stossel, 2006). 
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Whereas ROCK inhibited Rac, mDia was found to activate Rac in the same cells, 
independently of ROCK, through the Cas/DOCK180 pathway (Tsuji et al., 2002; 
Yamana et al., 2006). The fact that the knockdown of RhoA in StarD13 knockdown cells 
caused the total disappearance of focal adhesions supports the idea that these structures 
are caused by the constitutive activation of RhoA in the absence of StarD13. It is 
important to note that no focal adhesions were observed in these cells. The knockdown 
of RhoA was not able to reverse the inhibition in motility caused by the knockdown of 
StarD13, as normal focal adhesion formation is needed for efficient cell migration. This 
is consistent with the fact that the knock down of both RhoA and Rac in StarD13 knock 
down cells completely paralyzed the cells.  
Our hypothesis that the knockdown of StarD13 is inhibiting cell motility through 
the constitutive activation of RhoA is also highly reinforced by the results of the time-
lapse RhoA pull down assay following EGF stimulation, showing that RhoA undergoes 
cycles of activation and inactivation, and that this cycling is abolished when StarD13 is 
absent. Spatial and temporal analysis of RhoA activation by time-lapse FRET showed 
that the cycling of RhoA occurs at both the tail and the leading edge of cells. The 
inhibition of RhoA at the leading edge of cells is most probably important for the 
activation of Rac and the subsequent formation of focal contacts (Figure 8, right panel). 
FRET analysis also showed that in the absence of StarD13 there is a persistent high 
activity of RhoA in focal adhesions at the cell tail and the leading edge of cells. 
Altogether, this data suggests that StarD13 is necessary for the inhibition of RhoA both 
at the cell tail, a process needed for tail retraction, and at the cell front which is needed 
in order for Rac to activate and induce the formation of focal complexes. Then, the 
activation of RhoA at the cell edge is needed for these focal complexes to mature 
generating the necessary tension for the cell to move forward.  
This paper also shows that RhoA should be activated at the leading edge of 
astrocytoma cells, as previously established for breast cancer cells (El-Sibai et al., 2008). 
The role of RhoA at the edge is to allow the maturation of Rac-mediated focal 
complexes into focal adhesions since the absence of RhoA leads to the absence of focal 
adhesions and the accumulation of focal complexes (El-Sibai et al., 2008). Even though 
protrusion is unaffected, the absence of focal adhesions leads to an ineffective protrusion 
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with not enough traction force on the ECM for the cells to move forward (Gupton, & 
Waterman-Storer, 2006). In this system and in other systems (El-Sibai et al., 2008), we 
have shown that defective adhesions due to inhibition of Rac or RhoA, though they do 
not affect protrusion, inhibit cell motility. Hence, as we describe a need to inhibit RhoA 
at the tail of cells, we also confirm the newly described role of RhoA at the leading edge 
of cancer cells undergoing movement, contrary to the canonical distribution of RhoA 
activation (Figure 7).  
This work establishes that in addition to the activation of RhoA needed for the 
stabilization of protrusions (at the cell edge) and the generation of contractile force 
(along the cell body), an equally important event in the cell motility cycle is the 
inactivation of RhoA in focal adhesions at the cell tail. This is needed for the dissolution 
of these adhesions and the successful retraction of the tail. This work also defines 
StarD13, which is probably one member of a whole orchestra of GEFs and GAPs 
coordinating the activation and inactivation of RhoA respectively, as an important 
regulator of the cell motility cycle. 
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Chapter V 
CONCLUSION 
 
As was expected, StarD13 was found to regulate cancer cell motility. As was 
described in the literature, StarD13 was found to have GAP characteristics on both 
RhoA and Cdc42. StraD13 was found to regulate motility by affecting RhoA activity, 
which in turn regulates Rac1 activity. Rac1 and RhoA were described in this paper to be 
major controllers of the actin cytoskeleton. In depth of RhoA activation revealed its 
cyclic characteristic. RhoA was also found to be mostly active on the cell edges and a 
key process for tail retraction. RhoA was also studied for formation focal adhesions 
while Rac1 was studied for its critical role in the formation of focal complexes. These 
two phenotypes were found important for adhesion and the completion of the cell 
motility cycle.  
 RhoA could be targeted to keep it bound to GDP in its inactive form. This approach 
will deregulate the ability of the cell to migrate. Targeting RhoA alone might not be 
solely sufficient to completely inhibit cell motility cycle, since Rac also regulates a 
lesser type of actin structures aiding in motility. An efficient drug would target both 
RhoA and Rac1. Further work should be done in vivo and in 3D, which would shed light 
on the actual events of cell migration, metastasis and its regulators. 
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